

## Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series

Michael G Argenziano *medical student*<sup>\*1,2</sup>, Samuel L Bruce *medical student*<sup>\*1,2</sup>, Cody L Slater *medical student*<sup>\*1,2</sup>, Jonathan R Tiao *medical student*<sup>\*1,2</sup>, Matthew R Baldwin *assistant professor of medicine*<sup>3</sup>, R Graham Barr *Hamilton Southworth professor of epidemiology and medicine*<sup>4</sup>, Bernard P Chang *assistant professor of emergency medicine*<sup>5</sup>, Katherine H Chau *cardiology fellow*<sup>6</sup>, Justin J Choi *assistant professor of medicine*<sup>7</sup>, Nicholas Gavin *assistant professor of emergency medicine*<sup>5</sup>, Parag Goyal *assistant professor of medicine*<sup>7</sup>, Angela M Mills *J.E. Beaumont professor and chair of emergency medicine*<sup>5</sup>, Ashmi A Patel *assistant professor of medicine*<sup>4</sup>, Marie-Laure S Romney *assistant professor of medicine*<sup>5</sup>, Monika M. Safford *John J. Kuiper professor of medicine*<sup>7</sup>, Neil W Schluger *professor of medicine*<sup>3</sup>, Soumitra Sengupta *associate professor of biomedical informatics*<sup>2</sup>, Magdalena E Sobieszczyk *associate professor of medicine*<sup>8</sup>, Jason E Zucker *instructor in medicine*<sup>8</sup>, Paul A Asadourian *medical student*<sup>1</sup>, Fletcher M Bell *medical student*<sup>1</sup>, Rebekah Boyd *medical student*<sup>1</sup>, Matthew F Cohen *medical student*<sup>1</sup>, MacAlistair I Colquhoun *medical student*<sup>1</sup>, Lucy A Colville *medical student*<sup>1</sup>, Joseph H de Jonge *medical student*<sup>1</sup>, Lyle B Dershowitz *medical student*<sup>1</sup>, Shirin A Dey *medical student*<sup>1</sup>, Katherine A Eiseman *medical student*<sup>1</sup>, Zachary P Girvin *medical student*<sup>1</sup>, Daniella T Goni *medical student*<sup>1</sup>, Amro A Harb *medical student*<sup>1</sup>, Nicholas Herzik *medical student*<sup>1</sup>, Sarah Householder *medical student*<sup>1</sup>, Lara E Karaaslan *medical student*<sup>1</sup>, Heather Lee *medical student*<sup>1</sup>, Evan Lieberman *medical student*<sup>1</sup>, Andrew Ling *medical student*<sup>1</sup>, Ree Lu *medical student*<sup>1</sup>, Arthur Y Shou *medical student*<sup>1</sup>, Alexander C Sisti *medical student*<sup>1</sup>, Zachary E Snow *medical student*<sup>1</sup>, Colin P Sperring *medical student*<sup>1</sup>, Yuqing Xiong *medical student*<sup>1</sup>, Henry W Zhou *medical student*<sup>1</sup>, Karthik Natarajan *assistant professor of biomedical informatics*<sup>2</sup>, George Hripcsak *Vivian Beaumont Allen professor of biomedical informatics, chair*<sup>2</sup>, Ruijun Chen *clinical assistant professor*<sup>2,6</sup>

\*Mr. Argenziano, Mr. Bruce, Mr. Slater, and Mr. Tiao contributed equally to this work.

<sup>1</sup>Columbia University Vagelos College of Physicians and Surgeons, New York, NY

<sup>2</sup>Department of Biomedical Informatics at Columbia University Medical Center, New York, NY

<sup>3</sup>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY

<sup>4</sup>Division of General Medicine, Department of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY

<sup>5</sup>Department of Emergency Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY

<sup>6</sup>Division of Cardiology, Department of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY

<sup>7</sup>Department of Medicine, Weill Cornell Medicine, New York, NY

<sup>8</sup>Division of Infectious Diseases, Department of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY

Word Count: 3088

Corresponding Authors: RuiJun Chen MD and George Hripcsak MD

RuiJun Chen MD

Department of Biomedical Informatics, Columbia University Irving Medical Center

[rc3179@cumc.columbia.edu](mailto:rc3179@cumc.columbia.edu)

972-762-4856

622 West 168th St., PH-20

New York, NY 10032

## ABSTRACT

**Objective:** To characterize patients with coronavirus disease 2019 (COVID-19) in a large New York City (NYC) medical center and describe their clinical course across the emergency department (ED), inpatient floors, and intensive care units (ICUs).

**Design:** Retrospective manual medical record review.

**Setting:** NewYork-Presbyterian/Columbia University Irving Medical Center (NYP/CUIMC), a quaternary care academic medical center in NYC.

**Participants:** The first 1000 consecutive patients with laboratory-confirmed COVID-19.

**Methods:** We identified patients with a positive RT-SARS-CoV-2 PCR receiving care at NYP/CUIMC from March 1 through April 15. Patient data was manually abstracted from the electronic medical record.

**Main outcome measures:** We describe patient characteristics including demographics, presenting symptoms, comorbidities on presentation, hospital course, time to intubation, complications, outcomes, and disposition.

**Results:** Among the first 1000 patients with confirmed COVID-19, 151 patients were discharged from or died in the ED, 618 were admitted to the floor, and 231 were admitted or transferred to the ICU; 195 remained hospitalized and 172 had died in the hospital. The most common presenting symptoms were cough (73.2%), fever (72.8%), and dyspnea (62.9%). Compared to Chinese and Italian cohorts, hospitalized patients and ICU patients in particular had more baseline comorbidities including hypertension, diabetes, and obesity and higher rates of acute kidney injury (AKI) and dialysis. ICU patients were older and predominantly male (67.5%); 75.3% developed AKI and 31.2% required dialysis. Notably, of patients who required mechanical ventilation, only 5.9% were first intubated more than 14 days after symptom onset. Time to intubation from symptom onset had a bimodal distribution, with modes at 3-4 and 9 days.

**Conclusions:** Hospitalized patients with COVID-19 illness at this medical center faced significant morbidity and mortality, with high rates of AKI, dialysis, and a bimodal distribution in time to intubation from symptom onset. Patients in this large sample had more baseline comorbidities and developed more complications than previous Italian and Chinese cohorts.

## INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a global pandemic, with New York City (NYC) as an epicenter of the disease. Since the first confirmed case of COVID-19 on March 1, 2020, there were 111,424 confirmed cases across the city, resulting in 29,741 hospitalizations and 6,840 confirmed deaths (as of April 15).<sup>1</sup> Internationally, the rapid spread of COVID-19 taxed hospital system resources and drove a scarcity of ventilators and other medical equipment in many countries.<sup>2</sup> Within NYC, the high burden of disease quickly exceeded the standard capacity of hospital systems, requiring massive expansion of inpatient and intensive care unit (ICU) facilities and raising concerns regarding optimal clinical management, safely maximizing hospital throughput, and resource allocation.<sup>3,4</sup>

Despite the pressing need for evidence to inform such key decisions, there remain limited data on COVID-19 in the U.S and how it compares with previously published international cohorts. Patient characteristics, illness course, practice patterns, resource utilization, morbidity, and mortality associated with COVID-19 have been characterized in only limited samples.<sup>5,6-8</sup> The U.S. effort at characterizing this disease began with two small case series from Seattle while internationally, Wuhan, China<sup>9-11</sup> and Lombardy, Italy<sup>12</sup> have published more extensively about their experiences. Characteristics of NYC patients are beginning to be enumerated with limited data on hospitalized patients, including the critically ill,<sup>13</sup> but it remains largely unknown how these patients compare to previously described U.S. and international cohorts and what implications these differences will have on clinical care, outcomes, and resources.<sup>7,14</sup>

Therefore, we sought to characterize the course of the first 1000 consecutive adult COVID-19 patients at NewYork-Presbyterian/Columbia University Irving Medical Center (NYP/CUIMC), a large quaternary care academic medical center. We present a detailed description of demographic data, comorbidities,

presenting symptoms, clinical course including time to intubation, hospital complications, and preliminary outcomes.

## **METHODS**

### **Data source and study sample**

We used data from the NYP/CUIMC electronic health record (EHR) and NYP clinical data warehouse to identify patients with laboratory-confirmed COVID-19 infection, as represented by a positive SARS-CoV-2-RT-PCR test, performed at the NYP/CUIMC Clinical Microbiology Laboratory between March 11 and April 15, 2020. We performed ongoing retrospective manual data abstraction from EHR charts of all patients with COVID-19 who received ED or inpatient care at NYP/CUIMC (excluding tests performed in the outpatient setting or at an outside hospital). We characterized the first 1000 consecutive patients with COVID-19.

NYP/CUIMC is a quaternary care academic medical center with 765 adult beds serving a diverse, high acuity patient population in the Manhattan borough of NYC.<sup>15</sup> NYP/CUIMC is comprised of Milstein Hospital, which includes 6 ICUs, and Milstein Heart Center, which includes an additional coronary and cardiothoracic ICU, for a total of 117 adult ICU beds.

### **Manual chart review**

Supervised by multiple clinicians and informaticians, an abstraction team of 30 trained medical students from the Columbia University Vagelos College of Physicians and Surgeons manually abstracted EHR data in chronological order by test date.<sup>16</sup> Information from the charts was collected using a REDCap<sup>16</sup> (a secure web application used to build clinical and translational databases) instrument previously designed at Weill Cornell Medicine.<sup>7</sup> Data collected included demographics, comorbidities, presenting

symptoms, laboratory and radiographic findings, hospital course including admission, ICU transfer, mechanical ventilation, complications (defined as those documented by clinicians in the EHR) such as acute respiratory distress syndrome (ARDS) or acute kidney injury (AKI), and disposition including discharge, transfer, or death.

### **Quality control (QC)**

The REDCap instrument collects 274 data fields, 90 of which are required. Records with missing data or with inconsistent times were reviewed by a second, dedicated QC abstractor. A random subsample was checked by a second abstractor, typically a clinician, for calibration and consistency. Any conflicting data were resolved by consensus.

### **Data characterization and analysis**

Individual records were labeled with the highest level of care a patient received as of April 15: (1) ED only, (2) floor admission, and (3) ICU admission. This paper includes those still hospitalized, discharged, or who died in the hospital. For patients with multiple COVID-19 related visits recorded in the EHR, the visit with the highest level of care was selected. For patients with multiple visits with the same level of care, the most recent visit was selected. Characteristics were stratified by the highest level of care received to date, and 95% confidence intervals (CIs) were recorded for each value.

All analysis and visualization were performed using R.<sup>17</sup> Continuous variables were represented as both mean with standard deviation and median with interquartile range. Relevant time differences were computed from EHR documented dates and times. Hartigan's dip test was used to test for multimodality.<sup>18</sup>

## **IRB Approval**

This study was approved by the Columbia University Institutional Review Board under protocol AAAS9834

## **Patient and Public Involvement**

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. While there are no plans to disseminate the results of the research to study participants or the relevant patient community, the preliminary results are publicly available on medRxiv.

## **RESULTS**

We characterized the first 1000 laboratory-confirmed patients who received ED or inpatient care at NYP/CUIMC from March 11 through April 15, 2020, with data collection ongoing for the remainder and any newly identified patients. Of this 1000 patient sample, there were 151 ED patients, 618 floor patients, and 231 ICU patients.

### **Baseline characteristics**

Table 1 presents a detailed breakdown of baseline characteristics including demographics, comorbidities, and home medications. The mean age was  $61.7 \pm 17.5$  years. There was a male predominance in the overall sample (59.6%) which was more pronounced among ICU patients (67.5%). The mean body mass index (BMI) for all patients was  $29.9 \pm 7.24$  kg/m<sup>2</sup> and highest among those in the ICU at  $31.2 \pm 8.0$  kg/m<sup>2</sup>. Hypertension was the most common comorbidity, present in 59.8% of patients, followed by diabetes in 37.2% (Table 1). Only 8.4% of patients reported no major comorbidities.



The most common home medications were statins (36.1%) and ACE-inhibitors (ACEi) or angiotensin receptor blockers (ARBs) (28.3%). The proportion of patients taking a home statin or ACEi/ARB increased across higher levels of care, but was not significantly different, except that ED patient had a significantly lower proportion of statin use. There was no difference across subgroups for NSAID use.

**Table 1**

	<b>Highest Level of Care</b>			
	<b>ED (n=151)</b>	<b>Floor (n=618)</b>	<b>ICU (n=231)</b>	<b>Overall (N=1000)</b>
<b>Age</b>				
Mean (SD)	55.6 (19.1)	63.0 (17.7)	62.2 (14.7)	61.7 (17.5)
Median [IQR]	55.0 [40.5-69.0]	64.0 [51.0-77.0]	63.0 [53.0-72.0]	63.0 [50.0-75.0]
<b>Age Category</b>				
18-34	24 15.9% [10.9 - 22.6]	51 8.3% [6.3 - 10.7]	12 5.2% [3 - 8.9]	87 8.7% [7.1 - 10.6]
35-54	48 31.8% [24.9 - 39.6]	142 23% [19.8 - 26.5]	53 22.9% [18 - 28.8]	243 24.3% [21.7 - 27.1]
55-64	32 21.2% [15.4 - 28.4]	138 22.3% [19.2 - 25.8]	67 29% [23.5 - 35.2]	237 23.7% [21.2 - 26.4]
65 and over	47 31.1% [24.3 - 38.9]	287 46.4% [42.5 - 50.4]	99 42.9% [36.6 - 49.3]	433 43.3% [40.3 - 46.4]
<b>Sex</b>				
Male	86 57% [49 - 64.6]	354 57.3% [53.3 - 61.1]	156 67.5% [61.2 - 73.2]	596 59.6% [56.5 - 62.6]
Female	65 43% [35.4 - 51]	264 42.7% [38.9 - 46.7]	75 32.5% [26.8 - 38.8]	404 40.4% [37.4 - 43.5]
<b>BMI</b>				
Mean (SD)	30.3 (6.90)	29.3 (6.86)	31.2 (8.03)	29.9 (7.24)
Median [IQR]	29.7 [25.9-32.9]	28.3 [25.0-32.7]	29.4 [25.7-34.2]	28.6 [25.2-33.1]
Missing	90	68	2	160
<b>Smoking Status</b>				
Never	119 78.8% [71.6 - 84.6]	478 77.3% [73.9 - 80.5]	175 75.8% [69.8 - 80.8]	772 77.2% [74.5 - 79.7]
Active	14 9.3% [5.6 - 15]	25 4.0% [2.8 - 5.9]	10 4.3% [2.4 - 7.8]	49 4.9% [3.7 - 6.4]
Former	18 11.9% [7.7 - 18.1]	115 18.6% [15.7 - 21.9]	46 19.9% [15.3 - 25.5]	179 17.9% [15.6 - 20.4]
<b>Multiple Visits</b>				
No	142 94.0% [89.1 - 96.8]	560 90.6% [88.1 - 92.7]	212 91.8% [87.5 - 94.7]	914 91.4% [89.5 - 93]
Yes	9	58	19	86

	6.0% [3.2 - 10.9]	9.4% [7.3 - 11.9]	8.2% [5.3 - 12.5]	8.6% [7 - 10.5]
<b>Total Number of Home Medications</b>				
Mean (SD)	3.62 (4.84)	5.63 (5.30)	5.02 (4.98)	5.19 (5.20)
Median [IQR]	1.00 [0-6.00]	5.00 [1.00-8.00]	4.00 [1.00-7.00]	4.00 [1.00-8.00]
<b>Length of Stay (Days)</b>				
Mean (SD)	-----	10.1 (3.99)	14.6 (5.94)	11.4 (5.01)
<b>Comorbidities</b>				
Hypertension	75 49.7% [41.8 - 57.6]	366 59.2% [55.3 - 63]	157 68.0% [61.7 - 73.6]	598 59.8% [56.7 - 62.8]
Diabetes Mellitus	39 25.8% [19.5 - 33.3]	233 37.7% [34 - 41.6]	100 43.3% [37.1 - 49.7]	372 37.2% [34.3 - 40.2]
Pulmonary Disease	35 23.2% [17.2 - 30.5]	133 21.5% [18.5 - 24.9]	54 23.4% [18.4 - 29.2]	222 22.2% [19.7 - 24.9]
CKD	12 7.9% [4.6 - 13.4]	98 15.9% [13.2 - 18.9]	27 11.7% [8.2 - 16.5]	137 13.7% [11.7 - 16]
Coronary Artery Disease	16 10.6% [6.6 - 16.5]	86 13.9% [11.4 - 16.9]	29 12.6% [8.9 - 17.4]	131 13.1% [11.1 - 15.3]
Asthma	25 16.6% [11.5 - 23.3]	59 9.5% [7.5 - 12.1]	29 12.6% [8.9 - 17.4]	113 11.3% [9.5 - 13.4]
Congestive Heart Failure	11 7.3% [4.1 - 12.6]	67 10.8% [8.6 - 13.5]	24 10.4% [7.1 - 15]	102 10.2% [8.5 - 12.2]
History of Stroke	7 4.6% [2.3 - 9.3]	53 8.6% [6.6 - 11]	19 8.2% [5.3 - 12.5]	79 7.9% [6.4 - 9.7]
COPD	10 6.6% [3.6 - 11.8]	42 6.8% [5.1 - 9.1]	14 6.1% [3.6 - 9.9]	66 6.6% [5.2 - 8.3]
Active Malignancy	4 2.6% [1 - 6.6]	48 7.8% [5.9 - 10.1]	14 6.1% [3.6 - 9.9]	66 6.6% [5.2 - 8.3]
Prior Transplant	5 3.3% [1.4 - 7.5]	28 4.5% [3.2 - 6.5]	11 4.8% [2.7 - 8.3]	44 4.4% [3.3 - 5.9]
Rheumatological Disease	2 1.3% [0.4 - 4.7]	24 3.9% [2.6 - 5.7]	9 3.9% [2.1 - 7.2]	35 3.5% [2.5 - 4.8]
Obstructive Sleep Apnea	1 0.7% [0.1 - 3.7]	16 2.6% [1.6 - 4.2]	7 3.0% [1.5 - 6.1]	24 2.4% [1.6 - 3.5]
Home Oxygen Requirement	4 2.6% [1 - 6.6]	13 2.1% [1.2 - 3.6]	5 2.2% [0.9 - 5]	22 2.2% [1.5 - 3.3]
HIV	1 0.7% [0.1 - 3.7]	14 2.3% [1.4 - 3.8]	6 2.6% [1.2 - 5.5]	21 2.1% [1.4 - 3.2]
Hepatitis B or C	2 1.3% [0.4 - 4.7]	12 1.9% [1.1 - 3.4]	4 1.7% [0.7 - 4.4]	18 1.8% [1.1 - 2.8]
Cirrhosis	0 0% [0 - 2.5]	10 1.6% [0.9 - 3]	5 2.2% [0.9 - 5]	15 1.5% [0.9 - 2.5]
Interstitial Lung Disease	1 0.7% [0.1 - 3.7]	10 1.6% [0.9 - 3]	2 0.9% [0.2 - 3.1]	13 1.3% [0.8 - 2.2]
Irritable Bowel Disease	0 0% [0 - 2.5]	9 1.5% [0.8 - 2.7]	3 1.3% [0.4 - 3.7]	12 1.2% [0.7 - 2.1]
Baseline Mechanical Ventilation	0 0% [0 - 2.5]	1 0.2% [0 - 0.9]	3 1.3% [0.4 - 3.7]	4 0.4% [0.2 - 1]
BMI > 30	29/61 47.5% [35.5 - 59.8]	214/550 38.9% [34.9 - 43]	107/229 46.7% [40.4 - 53.2]	350/840 47.5% [35.5 - 59.8]
No Major Comorbidities <sup>A</sup>	6 4% [1.8 - 8.4]	59 9.5% [7.5 - 12.1]	19 8.2% [5.3 - 12.5]	84 8.4% [6.8 - 10.3]
<b>Home Medications</b>				
Statins	36	233	92	361

	23.8% [17.7 - 31.2]	37.7% [34 - 41.6]	39.8% [33.7 - 46.3]	36.1% [33.2 - 39.1]
ACE Inhibitors/Angiotensin Receptor Blockers	31 20.5% [14.9 - 27.7]	182 29.4% [26 - 33.2]	70 30.3% [24.7 - 36.5]	283 28.3% [25.6 - 31.2]
NSAIDs	29 19.2% [13.7 - 26.2]	172 27.8% [24.4 - 31.5]	50 21.6% [16.8 - 27.4]	251 25.1% [22.5 - 27.9]
PPIs	14 9.3% [5.6 - 15]	113 18.3% [15.4 - 21.5]	36 15.6% [11.5 - 20.8]	163 16.3% [14.1 - 18.7]
Inhaled/Nasal Steroids	12 7.9% [4.6 - 13.4]	39 6.3% [4.7 - 8.5]	17 7.4% [4.6 - 11.5]	68 6.8% [5.4 - 8.5]
Oral Steroids	5 3.3% [1.4 - 7.5]	44 7.1% [5.3 - 9.4]	15 6.5% [4 - 10.4]	64 6.4% [5 - 8.1]

**Table 1. Cohort Characteristics** COVID-19 positive patients were stratified according to their highest level of care: (1) ED visit or discharge only, n = 151; (2) admission to the floor, n = 618; and (3) admission to the ICU, n = 231. For patients who have sought care multiple times, their highest level of care is reported here. Percentages and confidence intervals are listed below frequencies.

<sup>A</sup> No Major Comorbidities indicates patients who have none of the listed comorbidities.

Patients' most common presenting symptoms were cough (73.2%), fever (72.8%), and shortness of breath (62.9%) (Table 2). Dyspnea as a presenting symptom was significantly more common in those who progressed to the ICU, while floor patients had the highest rates of nausea and vomiting.

**Table 2**

	<b>Highest Level of Care</b>			
	<b>ED (n=151)</b>	<b>Floor (n=618)</b>	<b>ICU (n=231)</b>	<b>Overall (N=1000)</b>
Cough	116 76.8% [69.5 - 82.8]	450 72.8% [69.2 - 76.2]	166 71.9% [65.7 - 77.3]	732 73.2% [70.4 - 75.9]
Fever	111 73.5% [66 - 79.9]	448 72.5% [68.8 - 75.9]	169 73.2% [67.1 - 78.5]	728 72.8% [70 - 75.5]
Dyspnea	82 54.3% [46.4 - 62]	376 60.8% [56.9 - 64.6]	171 74% [68 - 79.3]	629 62.9% [59.9 - 65.8]
Myalgias	44 29.1% [22.5 - 36.8]	176 28.5% [25.1 - 32.2]	46 19.9% [15.3 - 25.5]	266 26.6% [24 - 29.4]
Diarrhea	30 19.9% [14.3 - 26.9]	156 25.2% [22 - 28.8]	48 20.8% [16 - 26.5]	234 23.4% [20.9 - 26.1]
Chills	23 15.2% [10.4 - 21.8]	120 19.4% [16.5 - 22.7]	38 16.5% [12.2 - 21.8]	181 18.1% [15.8 - 20.6]
Nausea/Vomiting	14 9.3% [5.6 - 15]	138 22.3% [19.2 - 25.8]	23 10% [6.7 - 14.5]	175 17.5% [15.3 - 20]
Headache	21 13.9% [9.3 - 20.3]	64 10.4% [8.2 - 13]	15 6.5% [4 - 10.4]	100 10% [8.3 - 12]
Sore Throat	17 11.3% [7.1 - 17.3]	48 7.8% [5.9 - 10.1]	19 8.2% [5.3 - 12.5]	84 8.4% [6.8 - 10.3]

Sputum	9 6% [3.2 - 10.9]	57 9.2% [7.2 - 11.8]	15 6.5% [4 - 10.4]	81 8.1% [6.6 - 10]
Rhinorrhea	15 9.9% [6.1 - 15.7]	45 7.3% [5.5 - 9.6]	18 7.8% [5 - 12]	78 7.8% [6.3 - 9.6]
Syncope	7 4.6% [2.3 - 9.3]	34 5.5% [4 - 7.6]	7 3% [1.5 - 6.1]	48 4.8% [3.6 - 6.3]
Conjunctival Congestion	0 0% [0 - 2.5]	2 0.3% [0.1 - 1.2]	3 1.3% [0.4 - 3.7]	5 0.5% [0.2 - 1.2]

**Table 2. Presenting Symptoms** The presenting symptoms of COVID-19 positive patients receiving care at NYP/CUIMC are detailed above in order of overall prevalence. Percentages and confidence intervals are listed below frequencies.

### Inpatient Hospital Course

Table 3 provides an overview of the hospital course of the inpatient cohort. Of the 1000 patients, 805 patients reached a primary endpoint as of April 15 - 633 patients discharged, 172 died, and 195 patients are still hospitalized. Of the 151 ED patients 85.4% of patients were discharged and 14.6% died prior to admission; of the 618 floor patients, 12.8% died. There were 231 ICU patients; 93.1% were intubated at least once, 22.5% were extubated at least once, and 8.7% were discharged; 30.7% of ICU patients died in the hospital and 60.6% remain hospitalized.

Overall, 64.2% of patients received over 48 hours of antibiotic therapy during their stay (most commonly azithromycin) and 63.6% received hydroxychloroquine (Table 3). Both treatments were more prevalent in ICU patients, with 93.5% on antibiotics and 88.3% on hydroxychloroquine; 93.5% of patients in the ICU received vasopressors at some point during their hospital course.

Across all patients with COVID-19, 32.9% developed acute kidney injury (AKI) and 12.6% required inpatient hemodialysis (Table 3). In the ICU, AKI and hemodialysis were even more common at 75.3% and 31.2%, respectively. Acute respiratory distress syndrome (ARDS) was diagnosed in 35% of all patients and 90% of ICU patients.

**Table 3**

	<b>Highest Level of Care</b>			
	<b>ED (n=151)</b>	<b>Floor (n=618)</b>	<b>ICU (n=231)</b>	<b>Overall (N=1000)</b>
Currently in Hospital	0 0% [0 - 2.5]	55 8.9% [6.9 - 11.4]	140 60.6% [54.2 - 66.7]	195 19.5% [17.2 - 22.1]
Discharged	129 85.4% [78.9 - 90.2]	484 78.3% [74.9 - 81.4]	20 8.7% [5.7 - 13]	633 63.3% [60.3 - 66.2]
Died in Hospital	22 14.6% [9.8 - 21.1]	79 12.8% [10.4 - 15.6]	71 30.7% [25.1 - 37]	172 17.2% [15 - 19.7]
Intubated (at least once)	12 <sup>A</sup> 7.9% [4.6 - 13.4]	3 <sup>A</sup> 0.5% [0.2 - 1.4]	215 93.1% [89 - 95.7]	230 23% [20.5 - 25.7]
Extubated (at least once)	1 <sup>B</sup> 0.7% [0.1 - 3.7]	1 <sup>B</sup> 0.2% [0 - 0.9]	52 22.5% [17.6 - 28.3]	54 5.4% [4.2 - 7]
Patients with Multiple Visits	9 6% [3.2 - 10.9]	58 9.4% [7.3 - 11.9]	19 8.2% [5.3 - 12.5]	86 8.6% [7 - 10.5]
COVID Positive >7 days after arrival	0 0% [0 - 2.5]	6 1% [0.4 - 2.1]	8 3.5% [1.8 - 6.7]	14 1.4% [0.8 - 2.3]
<b>Inpatient Medications</b>				
Ace Inhibitors/ Angiotensin Receptor Blockers	-----	31 5% [3.6 - 7]	6 2.6% [1.2 - 5.5]	37 4.4% [3.2 - 5.9]
Diuretics	-----	73 11.8% [9.5 - 14.6]	165 71.4% [65.3 - 76.9]	238 28% [25.1 - 31.1]
Inotropes	-----	0 0% [0 - 0.6]	23 10% [6.7 - 14.5]	23 2.7% [1.8 - 4]
NSAIDs	-----	89 14.4% [11.9 - 17.4]	24 10.4% [7.1 - 15]	113 13.3% [11.2 - 15.8]
Statins	-----	155 25.1% [21.8 - 28.6]	56 24.2% [19.2 - 30.2]	211 24.9% [22.1 - 27.9]
Vasopressors	-----	19 3.1% [2 - 4.8]	216 93.5% [89.6 - 96]	235 27.7% [24.8 - 30.8]
IVIG	-----	4 0.6% [0.3 - 1.7]	4 1.7% [0.7 - 4.4]	8 0.9% [0.5 - 1.8]
Kaletra	-----	1 0.2% [0 - 0.9]	1 0.4% [0.1 - 2.4]	2 0.2% [0.1 - 0.9]
Hydroxychloroquine	-----	336 54.4% [50.4 - 58.3]	204 88.3% [83.5 - 91.8]	540 63.6% [60.3 - 66.8]
Remdesivir	-----	8 1.3% [0.7 - 2.5]	10 4.3% [2.4 - 7.8]	18 2.1% [1.3 - 3.3]
Sarilumab	-----	3 0.5% [0.2 - 1.4]	17 7.4% [4.6 - 11.5]	20 2.4% [1.5 - 3.6]
Steroids	-----	57 9.2% [7.2 - 11.8]	101 43.7% [37.5 - 50.2]	158 18.6% [16.1 - 21.4]
Oseltamivir	-----	2 0.3% [0.1 - 1.2]	1 0.4% [0.1 - 2.4]	3 0.4% [0.1 - 1]
Tocilizumab	-----	14 2.3% [1.4 - 3.8]	35 15.2% [11.1 - 20.3]	49 5.8% [4.4 - 7.5]
<b>All Antibiotics</b>	-----	329 53.2% [49.3 - 57.1]	216 93.5% [89.6 - 96]	545 64.2% [60.9 - 67.3]
Azithromycin	-----	238 38.5% [34.8 - 42.4]	163 70.6% [64.4 - 76.1]	401 47.2% [43.9 - 50.6]
Ceftriaxone	-----	116 18.8% [15.9 - 22]	76 32.9% [27.2 - 39.2]	192 22.6% [19.9 - 25.5]
Doxycycline	-----	31 5% [3.6 - 7]	17 7.4% [4.6 - 11.5]	48 5.7% [4.3 - 7.4]

Levofloxacin	-----	6 1% [0.4 - 2.1]	8 3.5% [1.8 - 6.7]	14 1.6% [1 - 2.7]
Meropenem	-----	8 1.3% [0.7 - 2.5]	41 17.7% [13.4 - 23.2]	49 5.8% [4.4 - 7.5]
Zosyn	-----	68 11% [8.8 - 13.7]	167 72.3% [66.2 - 77.7]	235 27.7% [24.8 - 30.8]
Vancomycin	-----	29 4.7% [3.3 - 6.7]	112 48.5% [42.1 - 54.9]	141 16.6% [14.3 - 19.3]
Other Antibiotics	-----	48 7.8% [5.9 - 10.1]	52 22.5% [17.6 - 28.3]	100 11.8% [9.8 - 14.1]
<b>Hospital Complications</b>				
ARDS	-----	89 14.4% [11.9 - 17.4]	208 90% [85.5 - 93.3]	297 35% [31.8 - 38.3]
AKI	-----	105 17% [14.2 - 20.2]	174 75.3% [69.4 - 80.4]	279 32.9% [29.8 - 36.1]
ARDS + Additional Complication <sup>c</sup>	-----	44 7.1% [5.3 - 9.4]	195 84.4% [79.2 - 88.5]	239 28.2% [25.2 - 31.3]
Other Complication	-----	103 16.7% [13.9 - 19.8]	98 42.4% [36.2 - 48.9]	201 23.7% [20.9 - 26.6]
Septic Shock	-----	16 2.6% [1.6 - 4.2]	162 70.1% [63.9 - 75.7]	178 21% [18.4 - 23.8]
Inpatient Dialysis	-----	35 5.7% [4.1 - 7.8]	72 31.2% [25.5 - 37.4]	107 12.6% [10.5 - 15]
New Onset Arrhythmia	-----	19 3.1% [2 - 4.8]	43 18.6% [14.1 - 24.1]	62 7.3% [5.7 - 9.3]
Ventilator-Associated Pneumonia	-----	0 0% [0 - 0.6]	35 15.2% [11.1 - 20.3]	35 4.1% [3 - 5.7]
New Onset HF	-----	7 1.1% [0.5 - 2.3]	17 7.4% [4.6 - 11.5]	24 2.8% [1.9 - 4.2]
Rhabdomyolysis	-----	1 0.2% [0 - 0.9]	6 2.6% [1.2 - 5.5]	7 0.8% [0.4 - 1.7]
MI	-----	4 0.6% [0.3 - 1.7]	2 0.9% [0.2 - 3.1]	6 0.7% [0.3 - 1.5]
Mechanical Circulatory Support	-----	0 0% [0 - 0.6]	5 2.2% [0.9 - 5]	5 0.6% [0.3 - 1.4]
DIC	-----	0 0% [0 - 0.6]	4 1.7% [0.7 - 4.4]	4 0.5% [0.2 - 1.2]

**Table 3. Inpatient Characteristics, Medications, and Complications** Patients receiving care at NYP/CUIMC ED were stratified according to the highest level of care received during their hospitalization. These categories include (1) ED visit or discharge only, n = 151; (2) admission to the floor, n = 618; and (3) admission to the ICU, n = 231. Notably, 195 out of 1000 patients are still in the hospital. The intubated patient row includes all patients who were intubated at least once – they may be intubated, extubated, re-intubated, or dead. Extubated patients include any patient who was extubated including those who died in the hospital afterwards. It is important to note that many patients have not reached the end of their hospital course and that their charts are actively being reviewed. These are the outcomes reviewed as of April 15, 2020.

<sup>A</sup> Patients who were intubated in the ED/on the floor but died before reaching the ICU

<sup>B</sup> Patients who were palliatively extubated or switched to DNR status before reaching the ICU

<sup>C</sup> Patients with both ARDS and any of AKI, septic shock, dialysis requirement, DIC, new onset arrhythmia, MI, new onset heart failure, or rhabdomyolysis

## Time Course of Intubated Patients

The time from the first reported symptoms to initial intubation (for the 135 intubated patients with exact date of first symptom recorded) appears bimodal ( $p = 0.0088$  for multimodality by Hartigan's dip test), with modes at 3-4 days and at 9 days post symptom onset (Figure 1). For patients who ultimately required mechanical ventilation, 94.1% were first intubated within 14 days after symptom onset. Additionally, 71.1% were intubated within the first three days after ED arrival (Supplemental Figure 1).

Figure 2 displays the hospital timeline for each intubated patient, starting from ED presentation, and stratified by clinical status (death, discharge, or currently hospitalized). For the 230 intubated patients, 23.5% were extubated at least once, 32.6% died in the hospital, 5.7% were discharged from the hospital, and 58.7% were still hospitalized. Mean time of invasive mechanical ventilation (for first intubation) was  $5.4 \pm 5.4$  days in patients who died,  $8.2 \pm 2.9$  days in patients who were discharged, and  $12.2 \pm 5.7$  days in patients who were still hospitalized.

## DISCUSSION

In our characterization of the first 1000 consecutive patients with COVID-19 who received ED or inpatient care at NYP/CUIMC, we found a bimodal distribution for time to intubation from symptom onset. As compared to previously published samples, our cohort had more baseline comorbidities and developed more complications, with high rates of AKI, inpatient dialysis, and prolonged intubation time and lengths of stay. This study represents one of the first large, detailed characterizations of hospitalized patients with COVID-19 in NYC and in the US. Through manually abstracted data, this retrospective study provides an in-depth description of these patients at a more granular level than prior literature, including a previously undescribed bimodal distribution for time to intubation, which may suggest a biphasic nature to the COVID-19 disease process. We hope a better understanding of our patient

population, baseline characteristics, inpatient course, and clinical outcomes can provide valuable guidance to clinicians who are working in a time of unparalleled volume and uncertainty.

As compared with prior literature, we found higher rates of renal complications in our patient sample. Previous studies from China reported 15% of all COVID-19 patients developed AKI,<sup>10</sup> while a case series of 21 critically ill patients in Seattle found 4 patients (19.1%) developed AKI.<sup>6</sup> However, we found 32.9% of all COVID-19 patients and 75.3% of ICU patients developed AKI, a striking increase compared to previous reports. Concomitantly, 12.6% of all patients and 31.2% of ICU patients required inpatient hemodialysis, which has led to a scarcity of equipment needed for dialysis and continuous renal replacement therapy (CRRT). Similar experiences with slightly lower rates of AKI and CRRT leading to the scarcity of dialysis resources have been reported in other NYC hospitals<sup>7</sup>. This has resulted in the sharing of dialysis machines across patients, even for CRRT within the ICU setting. There may be multiple explanations for these differences. As part of treating patients with ARDS, providers often limit use of intravenous fluids, and this initial lung-protective fluid management strategy may have incidentally led to higher rates of AKI. Alternatively, there may be inherent renal toxicity associated with the pathophysiology of COVID-19 viral infection, given that the rates of AKI even in non-ICU patients or those without ARDS remain high. These rates may also be relatively higher than previous literature due to the relatively high acuity and increased comorbidities of our patient population at baseline.

Relative to previously published cohorts, our patients have a higher average BMI, greater prevalence of hypertension, diabetes, and COPD, while fewer patients in our overall cohort have no major comorbidity (8.4% vs. 32% and 52%) relative to the cohorts characterized in Italy and China.<sup>2 10 12 19</sup> During the time of this series, NYC encouraged mildly symptomatic patients to stay home, and NYP/CUIMC implemented extensive triaging practices (including cough/cold/fever clinics, evaluation and tents outside of



emergency departments (ED) and telemedicine follow-up) to manage patients without severe dyspnea at home. Thus, the patients in this cohort likely represented a higher acuity subset of symptomatic cases. Despite this, patients with COVID-19 in this sample have thus far had similar mortality to those presented in the epicenters of other countries. Across all levels of care, 17.2% of patients died, which is similar to NYU (18.5%)<sup>14</sup> and lies in between estimates from China (1.4%, 28%).<sup>10 11 20</sup> Our current mortality rate of ICU patients is 30.7%, while prior reports have suggested highly variable mortality rates in Italy (26%), China (38%, 78%), and Seattle (50%, 67%).<sup>6 8-10 12</sup> However, 60.6% of ICU patients remain hospitalized, and the true mortality number will likely be higher.

The characterizations of prolonged intubation course and bimodal distribution in time to intubation from symptom onset may help clinicians identify when patients are at high risk and anticipate disease progression. Of the 230 patients intubated at least once, 94.1% were intubated within the first 14 days of symptom onset, with bimodal peaks at 3-4 days and 9 days from symptom onset. Patients often undergo rapid respiratory decompensation, leading to increased clinician uncertainty. These findings may encourage plans for continued monitoring and vigilance despite clinical stability or improvement if a patient is in between the 3-4 and 9-day peaks. On the other hand, it may reassure providers to de-escalate or discharge when patients are on a stable or improving trajectory after 14 days of symptoms, effectively suggesting they are at lower risk of further decompensation, thereby optimizing hospital beds and resource utilization. This pattern may be due to the underlying pathophysiology, different response groups or phenotypes of patients who develop critical illness at different times, or differing practice patterns. In previous reports from China, patients tended to develop ARDS around day 12.<sup>10</sup> Another paper from Italy hypothesized that older patients with COVID-19 tend to become dyspneic around 5-7 days after symptom onset, while younger patients tend to develop dyspnea later in the

course.<sup>5</sup> Further work is necessary to understand the mechanisms driving this distribution of intubation times, as it could dictate the timing of interventions and treatments.

Length of stay (LOS) and total time on mechanical ventilation remains high for these patients, with significant implications for post-recovery needs and sequelae. Our total cohort had a median LOS of 11.4 ± 5.0 days (14.6 ± 5.9 days for ICU patients), comparable to two cohorts in China with median LOS of 11 and 12 days respectively, with the former study reporting an ICU LOS of 8 days.<sup>10,11</sup> However, our ICU median LOS will continue to rise, given that 60.6% of ICU patients were still hospitalized as of last review. Among ICU patients, the mean time on mechanical ventilation for our currently hospitalized patients was over 12 days and rising, which exceeds the average LOS for the entire hospitalization of most patients in China. While alarmingly long, this hospital course is comparable to the LOS of influenza patients requiring intubation. Critically ill influenza patients have been reported to have a median intubation duration of 10-12 days,<sup>22</sup> a duration comparable to this cohort's LOS of 11 days, which may help provide guidance on post-ICU care for these patients. These lengthy intubations and hospitalizations have profound implications for rehabilitation, critical illness neuropathy, discharge planning, physical therapy,<sup>23-25</sup> increased home support and needs during a time of social distancing, and potential difficulty in returning to baseline functional status.

As the COVID-19 pandemic progresses alongside a mounting resource scarcity, the characterization of these patients and outcomes may be more representative of the evolving clinical presentation and course that hospitals and patients across the US and the world may expect to see. These results can help guide the development of patient protocols (such as safe discharge guidelines and follow-up practices), inform emergency medical system responses, and drive the continued growth of telemedicine and remote patient monitoring.<sup>26</sup> While an understanding of our experience may be helpful to hospitals and

healthcare workers as they prepare to triage patients, we recognize that COVID-19 patients who require hospital admission will have a high morbidity and mortality, and a high percentage will require ICU beds, ventilators, or dialysis. These sobering facts should motivate continued efforts to further investigate a potential biphasic disease course suggested by the bimodal distribution of intubations, model the resource needs across hospitals and countries based on these rising rates of complications, and continue to develop interventions to change the course of the disease.

## **STUDY LIMITATIONS**

This study has several limitations. First, data collection is limited to what is documented in the EHR. There may be errors in both patient recall and clinician documentation. Second, accuracy of data is limited by the accuracy of the data abstraction itself. We attempt to mitigate this potential error with both manual QC and by implementing a series of checks in the data after it is downloaded from the REDCap database. Third, not all patients included in this paper have completed their hospital course and could switch into a different level of care, i.e. a patient who is currently on the floor may be admitted to the ICU next week. However, the urgency for data to inform clinicians motivates us to provide this snapshot of patients at the point of last data abstraction on April 15, 2020. We deliberately focused on characterizing the data in this paper to provide descriptive statistics and figures, and do not perform hypothesis driven statistical inference. Finally, data were collected from a single, urban academic medical center and may not be generalizable to all other regions.

## **CONCLUSION**

Hospitalized patients with COVID-19 in NYC may be higher-risk at baseline with more comorbidities and develop more complications, as compared to previously published U.S. and international cohorts. These patients face significant morbidity and mortality, with high rates of AKI, dialysis, and a bimodal

distribution of time to intubation from symptom onset. This characterization of COVID-19 patients in NYC may provide anticipatory guidance as the pandemic continues around the world.

## **SUMMARY BOX**

### **What is already known on this topic**

- Coronavirus disease 2019 (COVID-19) is a global pandemic, with New York City (NYC) as a new epicenter of the disease.
- The high burden of disease has quickly exceeded the standard capacity of hospital systems and raised concerns regarding optimal clinical management, safely maximizing hospital throughput, and resource allocation.
- Front-line healthcare providers have limited data to help anticipate the clinical course of these patients and how they compare to previous international cohorts.

### **What this study adds**

- Patients with COVID-19 requiring mechanical ventilation had a bimodal distribution in time to intubation from symptom onset, with the vast majority (94.1%) first intubated within 14 days.
- Hospitalized patients, specifically those in ICUs, had more comorbidities compared to previous international cohorts, along with higher rates of AKI and dialysis.
- These findings may help inform front-line providers and provide anticipatory guidance for the international community during this pandemic.

## ACKNOWLEDGEMENTS/STATEMENTS

### Author Contributions:

MGA, SLB, CLS, JRT contributed equally and share first authorship.

Study conception and design: MGA, SLB, CLS, JRT, GH, RC, KN, PG, MMS, JJC, FMB, LAC, KAE, ZPG, NH, SH, JHD, LEK, HL, AL, RL, ACS.

Acquisition, analysis, or interpretation of data: MGA, SLB, CLS, JRT, GH, RC, KHC, KN, PAA, FMB, RB, MFC, MIC, LAC, JHD, LBD, SAD, KAE, ZPG, DTG, AAH, NH, SH, LEK, HL, EL, AL, RL, AYS, ACS, ZES, CPS, YX, HWZ.

Drafting of the manuscript: MGA, SLB, CLS, JRT

Critical revision of the manuscript for important intellectual content: MGA, SLB, CLS, JRT, GH, RC, MRB, BPC, NG, PG, AMM, AAP, MSR, NWS, SS, MDS, RGB, KHC, JJC, MMS, JEZ.

Statistical analysis: MGA, SLB, CLS, JRT.

Administrative, technical, or material support: MGA, SLB, CLS, JRT, SS, GH, RC, KN.

Study supervision: GH, RC, KN.

GH and RC are the guarantors of the study

**Additional Contributions:** The authors would like to acknowledge the Weill Cornell Medicine COVID-19 Registry Team, which developed the chart abstraction tool used in this study and assisted with training of the VP&S medical students in the chart abstraction process.

**Conflict of Interest Disclosures:** All authors have completed the ICMJE uniform disclosure form and declare: MGA, SLB, CLS, JRT, MRB, BPC, NG, PG, AMM, AAP, MSR, NWS, SS, MDS, KN, PAA, FMB, RB, MFC, MIC, LAC, JHD, LBD, SAD, KAE, ZPG, DTG, AAH, NH, SH, LEK, EL, AL, AYS, ACS, ZES, CPS, YX, HWZ, and RL have no conflicts of interest or funding to disclose. RGB reports funding from the NIH and the COPD foundation. KHC reports being supported by an institutional grant by the National Institutes of Health/ National Heart, Lung, and Blood Institute. JJC receives research support from the NIH/NCATS, Allergan, and Roche Diagnostics on a topic unrelated to the content of this manuscript. MMS receive

grant support from Amgen to conduct investigation on cardiovascular disease risks and outcomes. JEZ is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. GH receives grant support by the National Institutes of Health. RC receives grant support by the National Institutes of Health. HL is funded by the NIH through the National Heart, Lung and Blood Institute.

**Funding/Support:** No funding organization or sponsor was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Ethics Approval:** This study was approved by the Columbia University Institutional Review Board under protocol AAAS9834.

**Data Sharing:** Requests for the statistical code and dataset can be made to the corresponding author.

**Exclusive License:** The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence

(<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution and convert or allow conversion into any format including without limitation audio, iii) create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. All research articles will be made available on an open access basis (with authors being asked to pay an open access fee—see <http://www.bmj.com/about-bmj/resources->

[authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse](#)). The terms of such open access shall be governed by a [Creative Commons](#) licence—details as to which Creative Commons licence will apply to the research article are set out in our worldwide licence referred to above.

**Data dissemination statement:** Dissemination to study participants and/or patient organizations is not applicable.

**Transparency declaration:** RC affirms that the manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted, and all discrepancies from the study as planned have been explained.



## **References:**

1. NYC Department of Health. COVID-19: Data 2020 [accessed 9 Apr 2020].
2. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. *N Engl J Med* 2020 doi: 10.1056/NEJMp2006141 [published Online First: 2020/03/27]
3. Prin M, Wunsch H. International comparisons of intensive care: informing outcomes and improving standards. *Curr Opin Crit Care* 2012;18(6):700-6. doi: 10.1097/MCC.0b013e32835914d5 [published Online First: 2012/09/08]
4. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *N Engl J Med* 2020 doi: 10.1056/NEJMs2005114 [published Online First: 2020/03/24]
5. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. Treasure Island (FL)2020.
6. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* 2020 doi: 10.1001/jama.2020.4326 [published Online First: 2020/03/20]
7. Goyal P CJ, Pinheiro LC, et al. Clinical Characteristics of COVID-19 in New York City. *N Engl J Med* 2020
8. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med* 2020 doi: 10.1056/NEJMoa2004500 [published Online First: 2020/04/01]
9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5 [published Online First: 2020/01/28]
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3 [published Online First: 2020/03/15]
11. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020 doi: 10.1056/NEJMoa2002032 [published Online First: 2020/02/29]
12. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020 doi: 10.1001/jama.2020.5394 [published Online First: 2020/04/07]
13. Cummings MJ BM, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. medRxiv: Columbia University Irving Medical Center, 2020.
14. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. *medRxiv* 2020
15. NYS Department of Health. NYS Health Profiles - New York Presbyterian - Columbia Presbyterian Center 2020 [accessed 4/14/2020 2020].
16. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010 [published Online First: 2008/10/22]
17. R: A language and environment for statistical computing [program]. Vienna, Austria: R Foundation for Statistical Computing, 2010.
18. Hartigan PM. Algorithm AS 217: Computation of the Dip Statistic to Test for Unimodality. *Journal of the Royal Statistical Society Series C (Applied Statistics)* 1985;34(3):320-25. doi: 10.2307/2347485

19. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *J Infect* 2020;80(4):388-93. doi: 10.1016/j.jinf.2020.02.016 [published Online First: 2020/03/01]
20. Beumer M, Koch R, van Beuningen D, et al. Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. *Journal of critical care* 2019;50:59-65.
21. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA* 2016;315(8):788-800. doi: 10.1001/jama.2016.0291 [published Online First: 2016/02/24]
22. Rello J, Rodriguez A, Ibanez P, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. *Crit Care* 2009;13(5):R148. doi: 10.1186/cc8044 [published Online First: 2009/09/15]
23. Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. *Crit Care Med* 2003;31(4):1012-6. doi: 10.1097/01.CCM.0000053651.38421.D9 [published Online First: 2003/04/12]
24. Kim MJ, Park YH, Park YS, et al. Associations Between Prolonged Intubation and Developing Post-extubation Dysphagia and Aspiration Pneumonia in Non-neurologic Critically Ill Patients. *Ann Rehabil Med* 2015;39(5):763-71. doi: 10.5535/arm.2015.39.5.763 [published Online First: 2015/11/26]
25. Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med* 2020 doi: 10.1056/NEJMc2008597 [published Online First: 2020/04/16]
26. Croce MA, Fabian TC, Davis KA, et al. Early and late acute respiratory distress syndrome: two distinct clinical entities. *J Trauma* 1999;46(3):361-6; discussion 66-8. doi: 10.1097/00005373-199903000-00001 [published Online First: 1999/03/24]


## Figure Captions

**Figure 1. Distribution of Time from First Symptom to Intubation** Out of the 230 total intubated patients, 135 had a recorded date for first symptom onset. These patients are visualized in this figure. Days from first symptom to first intubation follows a bimodal distribution ( $p = 0.0088$  for Hartigan's Dip Test<sup>18</sup>), with modes at 3-4 days and 9 days. 5.9% of patients are intubated for the first time over 14 days after the first recorded symptoms.

**Figure 2. Timeline of Intubated Patients** The time course for COVID-19 positive patients intubated with exact times of intubation documented in the EHR ( $n=223^A$ ) at CUIMC is shown above. Patients are separated based on their current endpoints, separated into death, discharge, or currently hospitalized. 135 patients<sup>B</sup> are still hospitalized, 13 have been discharged, 75 have died, and 54 have been extubated. <sup>A</sup>7 patients acquired COVID-19 after intubation and are excluded from this plot.

<sup>B</sup> Data collection remains ongoing for currently hospitalized patients.

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.20.20072116>; this version posted April 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



Legend ED to Intubation First Intubation Extubated Second Intubation Second Extubation

Death: mean ( $\pm$ SD) time of first intubation  $5.4\pm 5.4$  days

Discharge: mean ( $\pm$ SD) time of first intubation  $8.2\pm 2.9$  days

Still in Hospital: mean ( $\pm$ SD) time of first intubation  $12.2\pm 5.7$  days

Individual Patient

time

